Introduction {#S5}
============

Transfusions of packed red blood cells (RBCs) are life-saving and vital to caring for very low birth weight (VLBW; \<1250g) neonates. These infants require transfusions throughout their hospital stay primarily due to anemia of prematurity, which results from diminished RBC production, shortened RBC lifespan, and iatrogenic blood loss from frequent lab draws required for monitoring ([@R1]). At our center, and many others, infants are regularly exposed to older blood products due to the current policy of using dedicated blood donors. This policy designates a specific packed RBC unit, derived from one donor, to one infant, from which the infant receives RBCs each time a transfusion is required until the expiration date. This policy was initially instituted to reduce exposure to multiple donors and decrease transmission of viral pathogens ([@R2]). A consequence of this practice is that neonates receive older, stored RBCs with each subsequent transfusion. Several retrospective studies suggested that certain morbidities, such as necrotizing enterocolitis, sepsis, bronchopulmonary dysplasia, and retinopathy of prematurity, may be associated with RBC transfusions ([@R3]--[@R5]); in contrast, other studies did not observe such associations ([@R6], [@R7]).

In the United States, the Food and Drug Administration (FDA) mandates that RBCs may be stored for a maximum of 42 days ([@R8]). Approximately half of transfused RBC units are stored for 21 days or longer ([@R9], [@R10]). During storage, RBCs undergo mechanical and biochemical changes that reduce their recovery in vivo; this is termed the "RBC storage lesion" ([@R11], [@R12]). Damaged RBCs are rapidly cleared from the circulation by reticuloendothelial macrophages, mostly within the first hour post-transfusion ([@R13]). The catabolized hemoglobin iron is then released and binds to circulating transferrin in plasma; however, when the rate of iron egress from the macrophage exceeds transferrin-binding capacity, non-transferrin-bound iron (NTBI) is produced ([@R14], [@R15]). NTBI may cause oxidative damage and increase infectious risk ([@R16]). Studies in healthy adult human volunteers suggest that NTBI is not produced following transfusion unless the RBCs are stored for 35--42 days ([@R17]). Nonetheless, VLBW infants may have impaired hepcidin responses and decreased transferrin levels, resulting in a decreased capacity to handle the iron released following transfusion of older, stored RBCs ([@R18]--[@R20]). Thus, it is possible that NTBI is observed in transfused neonates following transfusion of RBCs stored for less than 35 days ([@R18]).

Furthermore, in murine and canine studies, increased NTBI levels and enhanced pro-inflammatory cytokine responses were observed in animals transfused with older RBCs ([@R21]--[@R23]). This inflammatory response may contribute to the mechanisms responsible for some adverse effects of RBC transfusions ([@R23]). Because the risk of acquiring serious neonatal morbidities may be associated with RBC transfusions, and because adult and animal studies suggest that longer storage duration prior to transfusion may increase adverse effects, we examined whether there is a relationship in transfused VLBW infants between the age of stored RBCs and circulating post-transfusion NTBI, serum iron, total bilirubin, and pro-inflammatory cytokine levels.

Methods {#S6}
=======

Study Participants {#S7}
------------------

Parents of preterm infants with birth weight less than 1250g were approached for consent from August 2013 through December 2014 at the Morgan Stanley Children's Hospital of New York Presbyterian Hospital-Columbia University Medical Center, a level IV Neonatal Intensive Care Unit. Patients were included if inborn or transferred from an outside hospital at less than 7 days of life. Patients were excluded if they had been transfused with platelets or fresh frozen plasma within 4 hours of the tested RBC transfusion or were in a moribund condition. Parental consent was obtained from all study patients upon enrollment.

Study Design {#S8}
------------

This single-center, prospective, observational study evaluated the relationship between the age of transfused RBCs and serum iron, total bilirubin, NTBI, and circulating inflammatory cytokines. Standard leukoreduced, irradiated, CMV-negative, packed RBCs stored in an additive saline solution were transfused via a peripheral intravenous line over 4 hours, as per protocol at our center. Twenty-two of 23 independent transfusions used RBCs stored in AS-3 (Nutricel®) storage solution; one transfusion was of RBCs stored in citrate-phosphate-dextrose-adenine (CPDA-1). All RBC units were standard packs of RBCs obtained from the local supplier; in most cases, the parent bag was irradiated prior to aliquoting into syringes for administration to the neonates in the study as needed. Transfusions were given at the discretion of the neonatology medical team, among whom transfusion practices are similar. The general transfusion threshold practice for VLBW infants in the NICU is to maintain hematocrit \>35% for those with severe cardiopulmonary disease requiring mechanical ventilation with significant oxygen requirement in the first week of life, \>30% for moderate cardiopulmonary disease and for major surgery in hemodynamically stable infants, and \>20% for growing stable infants without any oxygen requirement (the thresholds maybe slightly higher for ELBW infants). A pre-transfusion, 1ml heel stick or venous blood sample was drawn within 1-hour before transfusion and another 1ml sample was drawn at 2--6 hours (target 4 hours) post-transfusion. Infants were transfused between 10--20 ml/kg as clinically indicated (17.0 ± 3.3 ml/kg; mean ± SD) plus an additional 2ml to account for the blood obtained for this study. The study protocol was approved by the Columbia University Medical Center Institutional Review Board.

Laboratory Methods {#S9}
------------------

Samples were collected in an additive free, serum separator tube, allowed to clot for 20 minutes, and then centrifuged at 2800 × g for 10 minutes. Serum aliquots were frozen at −80 °C until testing. NTBI was measured using an ultrafiltration colorometric assay ([@R24], [@R25]). Serum iron was measured by a colorometric method following the manufacturer's instructions (Iron/TIBC Reagent Set, BQ Kits). Bilirubin was measured using standard clinical laboratory methodology in the New York Presbyterian Hospital Clinical Laboratory. IL-8 and MCP-1 were measured by solid phase sandwich ELISA (R&D Systems) following the manufacturer's instructions.

Data Analysis {#S10}
-------------

For each study patient, infant and maternal medical records were reviewed and clinical characteristics noted. Power analysis was not performed for this convenience sample. Difference between means was assessed by paired t-test. Correlation with storage age was determined by Pearson linear regression. Multivariable regression was used to test for potential confounding by volume of RBCs transfused (ml/kg), sepsis/bacteremia (yes/no), and requirement for intubation (yes/no). A value for *p* less than 0.05 was considered significant. Prism (GraphPad Software, Inc.; San Diego, California) was used for all analyses.

Results {#S11}
=======

Demographics and Clinical Characteristics {#S12}
-----------------------------------------

From August 2013 through December 2014, we enrolled 23 infants transfused with RBCs. Clinical characteristics of these infants are provided in [Table 1](#T1){ref-type="table"}. Median gestational age was 26 weeks (range 23--30 weeks) and median birth weight was 745g. Median pre-transfusion hematocrit was 29% and median storage age of transfused RBCs was 9 days (range 1--34 days).

Effect of RBC storage age on markers of extravascular hemolysis {#S13}
---------------------------------------------------------------

The study subjects demonstrated increased serum total bilirubin (mean change = 0.45 mg/dL; P\<0.05), iron (mean change = 21.4 µg/dL; *P*\<0.01), and NTBI (mean change = 0.37 µM; P\<0.05) levels post-transfusion, as compared to pre-transfusion ([Figure 1](#F1){ref-type="fig"}). However, only the change in circulating NTBI level was significantly and positively associated with RBC storage duration (*P*\<0.001, R^2^=0.44; [Figure 1f](#F1){ref-type="fig"}). This relationship was not affected by volume of RBCs transfused, presence of sepsis/bacteremia at the time of transfusion, or requirement for intubation in multivariable regression (data not shown). Furthermore, the lower limit of detection of the NTBI assay used is 0.87 µM ([@R25]). All (3/3) transfusions of RBC stored for ≥20 days and 10% (2/20) of transfusions of RBC stored for \<20 days were above the lower limit of detection at 4 hours after transfusion and below this limit prior to transfusion (*P*\<0.01 by Fisher's Exact Test). Of note, the three transfusions of RBC stored for ≥20 days also were stored for 13, 21, and 28 days following irradiation.

Effect of RBC storage age on pro-inflammatory cytokines {#S14}
-------------------------------------------------------

The VLBW neonates had increased serum MCP-1 levels post-transfusion (mean change = 386.5 µg/mL; *p*\<0.001; [Figure 2a](#F2){ref-type="fig"}); however, no significant changes in IL-8 levels were observed ([Figure 2b](#F2){ref-type="fig"}). Furthermore, changes in MCP-1 and IL-8 levels did not correlate with RBC storage duration ([Figure 2c,d](#F2){ref-type="fig"}). These relationships were not affected by volume of RBCs transfused, presence of sepsis/bacteremia at the time of transfusion, or requirement for intubation in multivariable regression (data not shown).

Discussion {#S15}
==========

This study demonstrates that transfusion of RBCs after longer refrigerator storage duration induces increasing circulating NTBI in VLBW preterm neonates. A recent study in healthy adults suggests that NTBI is not observed after transfusion until the RBCs are stored for ≥35 days ([@R17]). Substantial increases in circulating NTBI were also not observed in critically-ill children until the final two weeks of storage ([@R26]). Taken together, these results suggest that preterm neonates are more susceptible to producing NTBI following RBC transfusion and this pathologic form of iron can be observed robustly after transfusion of blood stored for only 20 days.

Circulating NTBI is iron that is neither bound to the physiologic iron-transport protein, transferrin, nor is a constituent of heme or ferritin ([@R14], [@R15]). In healthy individuals, little, if any, circulating NTBI is ever observed. Iron enters the plasma principally by recycling hemoglobin-iron derived from senescent erythrocytes by reticuloendothelial macrophages in the spleen, liver, and bone marrow ([@R27]). During routine refrigerated storage, a proportion of the RBCs become irreversibly damaged and are cleared by these reticuloendothelial macrophages ([@R28]). By FDA criteria, on average, up to 25% of the transfused RBCs may be rapidly cleared; because most of these damaged RBCs are cleared within the first hour of transfusion ([@R13]), the rate of iron influx into plasma can exceed the rate of iron acquisition by transferrin. This results in the production of circulating NTBI, which is a heterogeneous assortment of iron complexes (e.g., with albumin or citrate) ([@R14]). Neonates may be particularly prone to produce NTBI due to decreased concentrations of circulating transferrin and impaired hepcidin responses ([@R18]--[@R20]).

Accumulating evidence indicates that NTBI can cause adverse effects ([@R16]). In animal studies, even short durations of circulating NTBI enhanced the virulence of specific bloodstream pathogens ([@R22], [@R23], [@R29], [@R30]). In addition, increased NTBI in human serum samples obtained after transfusing 6-week old RBCs enhanced proliferation *in vitro* of a pathogenic strain of *Escherichia coli* ([@R24]). Similarly, following oral iron supplementation, the increased serum iron enhanced proliferation *in vitro* of several bacterial pathogens, including *E. coli* ([@R31]). Circulating NTBI is also associated with increased risks of infectious complications following myelosuppression for acute leukemia, where patients with plasma NTBI levels \>2 µM, like those observed in this study after transfusing RBCs stored for \>20 days, had a higher risk of Gram-negative sepsis (P = 0.0004) ([@R32]). This raises the possibility that the NTBI produced following some RBC transfusions may be responsible for the purported association between RBC transfusion and necrotizing enterocolitis ([@R3], [@R4]). Indeed, recent studies identified uropathogenic *E. coli*, a highly ferrophilic organism, as a risk factor for necrotizing enterocolitis ([@R33]). Finally, by participating in Fenton chemistry, NTBI causes oxidative damage, cytotoxicity, and enhances endothelial expression of adhesion molecules ([@R14], [@R15], [@R34], [@R35]). Indeed, Stark et al ([@R36]) showed that malondialdehyde, a marker of oxidative stress, correlates with NTBI levels observed following RBC transfusions in VLBW infants.

Despite the potential for NTBI to cause harm, the randomized clinical trials assessing the benefit of a fresher RBC transfusion policy have not observed clinically significant differences in outcome. In a similar population as the VLBW infants in this study, the Age of Red Blood in Premature Infants (ARIPI) Trial was a double-blind, randomized controlled trial in 377 premature infants with birth weights \<1250 grams randomized to a transfusion policy of "fresh" RBCs, stored for 7 days or less, as compared with the standard of care ([@R7]). The overall conclusion was that a fresh RBC transfusion policy did not improve outcomes in premature, VLBW infants. Notably, the median age of the standard of care RBCs in that trial was 14.6 days. In contrast, our study, in combination with others ([@R36], [@R37]), suggest that there is very little evidence of NTBI production after transfusing RBCs stored for less than 20 days. Thus, to the extent that NTBI is responsible for adverse effects of transfusing older, stored RBCs, an observable clinical difference would not be expected between the groups in the ARIPI trial. Furthermore, irradiation damages RBCs and prolonged storage following irradiation exacerbates the RBC storage lesion ([@R38], [@R39]). Thus, the practice of irradiating the parent bag prior to storage as opposed to the aliquoted syringe prior to transfusion may be responsible for exacerbating the hemolysis observed following RBCs stored for longer than 20 days. It was not possible to disentangle whether the prolonged storage following irradiation is responsible for the increases in NTBI observed in this observational study. Therefore, additional studies are recommended to assess the safety of transfusing RBCs stored for longer than 20 days along with the effects of storage following irradiation in this vulnerable patient population.

Following transfusion of longer stored RBCs, a pro-inflammatory cytokine response was observed in animal models ([@R21]), ([@R23]). Furthermore, these studies ([@R23]) suggest that intact, but damaged, RBCs are responsible for this inflammatory response. Similar to other studies ([@R37]), post-transfusion MCP-1 levels were increased in our study; however, a correlation with storage age was not examined previously. Given that increases in MCP-1 levels in our study did not correlate with increased RBC storage duration, these increases seem unrelated to older RBC transfusion and may be caused by a confounding factor. For example, the first heel stick pre-transfusion may cause localized inflammation that is then measured by the second post-transfusion heel stick. Without an appropriate control group of non-transfused VLBW infants (for example, those getting saline or albumin infusions instead of transfusion), this issue is difficult to resolve. Unfortunately, for ethical reasons, it is very difficult to identify and justify such a control group.

Other limitations of our study include the limited laboratory outcomes assessed due to the limited amount of serum collected from VLBW infants. Furthermore, this single-center study had a convenience sample of only 23 neonates. The challenges involved in obtaining informed consent and collecting these precious samples make it difficult to perform larger, more adequately powered studies. However, our main NTBI outcome is confirmed by other small studies in VLBW infants ([@R36], [@R40]). Finally, some infants were transfused prior to obtaining consent for this study and only samples from transfusions following informed consent were collected; thus, not all samples are from the first transfusion event of life.

In conclusion, this study confirms that transfusions of RBCs after longer storage durations are associated with increased NTBI, particularly after 20 days of storage. Although the clinical consequences of these findings remain to be determined, it is evident that the responses to RBC transfusion in VLBW preterm infants differs from those observed in healthy adult volunteers ([@R17]) and in older, critically-ill pediatric patients ([@R26]). Given the lack of clinical evidence supporting the safety in neonates of RBC transfusions stored for greater than 20 days ([@R7]), the policy of using the same dedicated donor unit per neonate, in which subsequent aliquots are stored for longer durations, should be revisited, paying particular attention to those units stored for greater than 20 days.
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![Effects of RBC transfusion on markers of hemolysis and iron status\
Pre- and post-transfusion serum total bilirubin **(a)**, iron **(b)**, and non-transferrin-bound iron **(c)** levels. Standard box and whisker plots in which the box represents the 25^th^, median, and 75^th^ percentile; the whiskers represent 5^th^ and 95^th^ percentile for the value. Gray lines represent each subject's pre- and post-transfusion analyte level. Linear regression of the age of the transfused RBC unit in days versus the change in analyte level from pre- to post-transfusion for serum total bilirubin **(d)**, iron **(e)**, and non-transferrin-bound iron **(f)**; dark dashed line denotes lower limit of detection for non-transferrin-bound iron (0.87 µM); \**P*\<0.05; \*\**P*\<0.01.](nihms893658f1){#F1}

![Effects of RBC transfusion on pro-inflammatory chemo/cytokine levels\
Pre- and post-transfusion circulating levels of monocyte chemoattractant (MCP)-1 **(a)** and interleukin (IL)-8 **(b)**. \*\*\**P*\<0.001. Linear regression of the age of the transfused RBC unit in days versus the change in analyte level from pre- to post-transfusion for MCP-1 **(c)** and IL-8 **(d)**.](nihms893658f2){#F2}

###### 

Patient Demographics

  Characteristic                                               Value (N=23)
  ------------------------------------------------------------ -----------------
  **Race - no. (%)**                                           
    **Caucasian**                                              6 (26%)
    **African-American**                                       5 (22%)
    **Hispanic**                                               10 (44%)
    **Asian**                                                  1 (4%)
    **Mixed Race**                                             1 (4%)
  **Male, - n (%)**                                            8 (35%)
  **Birth Weight, grams -- median \[range\]**                  745 (474--1020)
  **Gestational age at birth, weeks -- median \[range\]**      26 (23--30)
  **Age of infant at transfusion, days -- median \[range\]**   11 (4--45)
  **Age of transfused RBCs, days -- median \[range\]**         9 (1--34)
